SENVI is a research-stage biotech company developing senolytics to support healthier aging and cellular resilience across acute and chronic disease. Our platform combines a novel approach to senescence with a differentiated discovery pipeline designed to produce a portfolio of selective, next-generation therapies.
Senescent cell accumulation is a key driver of aging, disrupting tissue function and promoting inflammation. Because aging is slow and not yet a defined regulatory indication, we are advancing our lead compound, SNC711, toward IND in oncology, where disease and treatment reproduce the hallmarks of aging in a rapid timeframe.
The Preclinical Data is Building a Consistent Story
Our platform is designed to advance senolytic therapies across cancer, regenerative and anti-aging medicine, and chronic and degenerative disease.
01
Aging
Aged mice showed visible biological rejuvenation after as little as two doses, including increased activity and strength, hair regrowth, improved skin and coat quality, and better metabolic parameters, suggesting senescent cell clearance may not just slow decline but reverse markers of aging itself.
Biological Rejuvenation
02
Metabolic
In diet-induced obesity models, SNC711 reduced weight while preserving and enhancing muscle coordination and strength, addressing a key limitation of GLP-1 drugs, while slowing progression to diabetic glucose levels and reducing inflammatory markers, suggesting disease-modifying potential beyond weight loss.
Reduced Weight
03
Oncology
In oncology, where senescence may help tumors evade therapy, SNC711 drove complete tumor regression with a BRAF inhibitor in melanoma and increased cytotoxic T-cell infiltration 5–10x while substantially reducing tumor burden with checkpoint inhibition in pancreatic cancer, suggesting it may make existing therapies more effective and durable.
Tumors Evade Therapy
30+
Year in
business
30+
Year in
business
30+
Year in
business
Their accumulation disrupts tissue function, promotes chronic inflammation, and contributes to vascular stiffening, impairing normal repair and accelerating age-related decline.
AGING • METABOLIC DISEASE • ONCOLOGY • FIBROSIS • IMMUNE DYSFUNCTION • LONGEVITY
Across very different disease models, the common thread is the same: remove senescent cells and healthier biology begins to re-emerge.
Strategic Partnership
with OHSU Knight
Cancer Institute
Under the leadership of Dr. Brian Druker, the pioneer behind Gleevec and backed by a historic $2 billion endowment from Phil and Penny Knight, the OHSU Knight Cancer Institute provides unparalleled scientific infrastructure, translational expertise, and clinical rigor.
Through our strategic partnership, oncology serves as a rigorous and rapid proof of concept to establish senescent cell clearance, functional recovery, and safety through established FDA pathways, anchoring a platform designed to support healthier aging over the lifespan.